Sanhita Sinharay1, Dianne Lee1, Swati Shah1, Siva Muthusamy1, Georgios Z Papadakis1, Xiang Zhang2, Dragan Maric3, William C Reid1, Dima A Hammoud4. 1. Center for Infectious Disease Imaging (CIDI), Radiology and Imaging Sciences, Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA. 2. Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD 20850, USA. 3. Division of Intermural Research (DIR), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, Maryland, USA. 4. Center for Infectious Disease Imaging (CIDI), Radiology and Imaging Sciences, Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA. Electronic address: hammoudd@cc.nih.gov.
Abstract
INTRODUCTION: In vivo imaging biomarkers of various HIV neuropathologies, including dopaminergic dysfunction, are still lacking. Towards developing dopaminergic biomarkers of brain involvement in HIV, we assessed the pre and postsynaptic components of the dopaminergic system in the HIV-1 transgenic rat (Tg), a well-characterized model of treated HIV+ patients, using small-animal PET imaging. METHODS: Fifteen to 18 month-old Tg and wild type (WT) rats were imaged with both [18F]-FP-CMT, a dopamine transporter (DAT) ligand (n=16), and [18F]-Fallypride, a D2/D3 dopamine receptor (D2/D3DR) ligand (n=16). Five to 8 month-old Tg and WT rats (n=18) were also imaged with [18F]-FP-CMT. A subset of animals was imaged longitudinally at 7 and 17 months of age. Multiplex immunohistochemistry staining for DAT, tyrosine hydroxylase, D2DR, D3DR, GFAP, Iba1 and NeuN was performed on a subgroup of the scanned animals. RESULTS: [18F]-FP-CMT and [18F]-Fallypride binding potential (BPND) values were significantly lower in 15-18 month-old Tg compared to age-matched WT rats (p<0.0001 and 0.001, respectively). [18F]-FP-CMT BPND values in 5-8 month-old rats, however, were not significantly different. Longitudinal age-related decrease in [18F]-FP-CMT BPND was exacerbated in the Tg rat. Immunohistochemistry showed decreased staining of dopaminergic markers in Tg rats. Rats with higher serum gp120 had lower mean BPND values for both ligands. CONCLUSIONS: We found presynaptic and postsynaptic dopaminergic dysfunction/loss in older Tg compared to WT rats. We believe this to be related to neurotoxicity of viral proteins present in the Tg rats' serum and brain. ADVANCES IN KNOWLEDGE: Our findings confirm prior reports of neurobehavioral abnormalities suggestive of dopaminergic dysfunction in this model. They also suggest similarities between the Tg rat and HIV+ patients as far as dopaminergic dysfunction. IMPLICATIONS FOR PATIENT CARE: The Tg rat, along with the above-described quantitative PET imaging biomarkers, can have a role in the evaluation of HIV neuroprotective therapies prior to human translation. Published by Elsevier Inc.
INTRODUCTION: In vivo imaging biomarkers of various HIV neuropathologies, including dopaminergic dysfunction, are still lacking. Towards developing dopaminergic biomarkers of brain involvement in HIV, we assessed the pre and postsynaptic components of the dopaminergic system in the HIV-1 transgenic rat (Tg), a well-characterized model of treated HIV+ patients, using small-animal PET imaging. METHODS: Fifteen to 18 month-old Tg and wild type (WT) rats were imaged with both [18F]-FP-CMT, a dopamine transporter (DAT) ligand (n=16), and [18F]-Fallypride, a D2/D3 dopamine receptor (D2/D3DR) ligand (n=16). Five to 8 month-old Tg and WT rats (n=18) were also imaged with [18F]-FP-CMT. A subset of animals was imaged longitudinally at 7 and 17 months of age. Multiplex immunohistochemistry staining for DAT, tyrosine hydroxylase, D2DR, D3DR, GFAP, Iba1 and NeuN was performed on a subgroup of the scanned animals. RESULTS: [18F]-FP-CMT and [18F]-Fallypride binding potential (BPND) values were significantly lower in 15-18 month-old Tg compared to age-matched WT rats (p<0.0001 and 0.001, respectively). [18F]-FP-CMT BPND values in 5-8 month-old rats, however, were not significantly different. Longitudinal age-related decrease in [18F]-FP-CMT BPND was exacerbated in the Tg rat. Immunohistochemistry showed decreased staining of dopaminergic markers in Tg rats. Rats with higher serum gp120 had lower mean BPND values for both ligands. CONCLUSIONS: We found presynaptic and postsynaptic dopaminergic dysfunction/loss in older Tg compared to WT rats. We believe this to be related to neurotoxicity of viral proteins present in the Tg rats' serum and brain. ADVANCES IN KNOWLEDGE: Our findings confirm prior reports of neurobehavioral abnormalities suggestive of dopaminergic dysfunction in this model. They also suggest similarities between the Tg rat and HIV+ patients as far as dopaminergic dysfunction. IMPLICATIONS FOR PATIENT CARE: The Tg rat, along with the above-described quantitative PET imaging biomarkers, can have a role in the evaluation of HIV neuroprotective therapies prior to human translation. Published by Elsevier Inc.
Entities:
Keywords:
Dopaminergic system; HIV; Small animal PET; imaging biomarkers
Authors: Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus Journal: Curr HIV Res Date: 2012-07 Impact factor: 1.581
Authors: Wolf Wrasidlo; Leslie A Crews; Igor F Tsigelny; Emily Stocking; Valentina L Kouznetsova; Diana Price; Amy Paulino; Tania Gonzales; Cassia R Overk; Christina Patrick; Edward Rockenstein; Eliezer Masliah Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739
Authors: W Reid; M Sadowska; F Denaro; S Rao; J Foulke; N Hayes; O Jones; D Doodnauth; H Davis; A Sill; P O'Driscoll; D Huso; T Fouts; G Lewis; M Hill; R Kamin-Lewis; C Wei; P Ray; R C Gallo; M Reitz; J Bryant Journal: Proc Natl Acad Sci U S A Date: 2001-07-31 Impact factor: 11.205
Authors: Giovanni Schifitto; Bradford A Navia; Constantin T Yiannoutsos; Christina M Marra; Linda Chang; Thomas Ernst; Jeffrey G Jarvik; Eric N Miller; Elyse J Singer; Ronald J Ellis; Dennis L Kolson; David Simpson; Avindra Nath; Joseph Berger; Sharon L Shriver; Linda L Millar; Dodi Colquhoun; Robert Lenkinski; R Gilberto Gonzalez; Stuart A Lipton Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Adam R Denton; Srimal A Samaranayake; Kristin N Kirchner; Robert F Roscoe; Shane N Berger; Steven B Harrod; Charles F Mactutus; Parastoo Hashemi; Rosemarie M Booze Journal: J Neurovirol Date: 2019-05-17 Impact factor: 2.643
Authors: Andrea M Herrmann; Stephan Meckel; Matthew J Gounis; Leona Kringe; Edith Motschall; Christoph Mülling; Johannes Boltze Journal: J Cereb Blood Flow Metab Date: 2019-02-07 Impact factor: 6.200
Authors: David R Goulding; Andrew Kraft; Peter R Mouton; Christopher A McPherson; Valeria Avdoshina; Italo Mocchetti; G Jean Harry Journal: Neurotox Res Date: 2019-07-08 Impact factor: 3.911
Authors: Jessica M Illenberger; Steven B Harrod; Charles F Mactutus; Kristen A McLaurin; Asha Kallianpur; Rosemarie M Booze Journal: J Neuroimmune Pharmacol Date: 2020-06-12 Impact factor: 4.147
Authors: Adam R Denton; Charles F Mactutus; Almeera U Lateef; Steven B Harrod; Rosemarie M Booze Journal: J Neurovirol Date: 2021-05-18 Impact factor: 3.739
Authors: Zeping Wang; Maura M Manion; Elizabeth Laidlaw; Adam Rupert; Chuen-Yen Lau; Bryan R Smith; Avindra Nath; Irini Sereti; Dima A Hammoud Journal: AIDS Date: 2021-07-01 Impact factor: 4.632